Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by equities researchers at StockNews.com from a "buy" rating to a "strong-buy" rating in a report issued on Tuesday.

Separately, Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN traded up $0.25 during midday trading on Tuesday, reaching $32.74. 1,501,832 shares of the stock traded hands, compared to its average volume of 486,335. The stock has a market capitalization of $1.83 billion, a P/E ratio of 30.60 and a beta of 0.84. The company has a fifty day moving average of $34.57 and a 200 day moving average of $35.06. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by company insiders.

Remove Ads

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Raiffeisen Bank International AG purchased a new stake in Supernus Pharmaceuticals in the fourth quarter worth about $25,000. Versant Capital Management Inc boosted its position in shares of Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 1,109 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $42,000. Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after buying an additional 870 shares during the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new position in Supernus Pharmaceuticals during the 4th quarter valued at approximately $52,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.